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Background: The purpose of this research was to validate the low expression of L-selectin (CD62L) in natalizumab
(NTZ)-treated patients. CD62L is involved in rolling and transmigration of leukocyte cells. A correlation between
CD62LCD4+ T cells low expression and progressive multifocal leukoencephalopathy (PML) development has been
suggested in multiple sclerosis (MS) patients treated with NTZ.
Methods: We performed a flow cytometric analysis on peripheral blood mononuclear cells (PBMC); we collected from
23 healthy donors and 225 MS patients: untreated (n = 19) or treated with NTZ (n = 113), interferon-beta (n = 26),
glatiramer acetate (n = 26), fingolimod (n = 23) and rituximab (n = 18). We have also analysed two PML/IRIS (immune
reconstitution inflammatory syndrome) patients and four longitudinal samples of a NTZ-treated patients before and
during the development of a clinical asymptomatic magnetic resonance imaging (MRI) lesion confirmed as PML by
cerebrospinal fluid (CSF) examination. Thirty-five NTZ-treated patients were studied longitudinally with three samples
taken 4 months apart.
Results: The NTZ-treated patients showed a lower percentage of CD62L (33.68 %, n = 113) than first-line treated
patients (44.24 %, n = 52, p = 0.0004). NTZ effect was already clear during the first year of treatment (34.68 %; p = 0.0184);
it persisted in the following years and disappeared after drug withdrawal (44.08 %). Three percent of longitudinally
analysed patients showed a percentage of CD62LCD4+ T cells under a hypothetical threshold and one patient with
asymptomatic PML belongs to a group which expressed low percentage of CD62LCD4+ T cells.
Conclusions: Our research confirms that NTZ has a specific effect on CD62LCD4+ T cells consisting in decreasing of the
number of positive cells. The low level of CD62L found in a clinically asymptomatic PML patient strengthens its
potential usefulness as a biomarker of high PML risk in NTZ-treated patients. A larger study is required to better confirm
the data.
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Natalizumab (NTZ) (Tysabri©, Biogen Idec Inc.,
Cambridge, MA) is a humanized monoclonal antibody
which blocks the α4 subunit of the α4 integrins (α4β1
and α4β7) which is expressed on the surface of lympho-
cytes and leukocytes [1, 2]. α4β1 is required for endothe-
lial adhesion, and it facilitates migration of peripheral
blood lymphocytes to the brain via the blood-brain bar-
rier [1]. NTZ showed its efficacy in the multiple sclerosis* Correspondence: spadaro_michela@yahoo.it
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article, unless otherwise stated.(MS) treatment by reducing the annual relapse rate in two
clinical trials by 68 % [3, 4]. This monoclonal antibody is
currently considered to be one of the best therapeutical
options for patients with relapsing-remitting MS (RRMS)
not responding to traditional therapies [5].
The most fearsome clinical complication of NTZ
treatment is progressive multifocal leukoencephalopathy
(PML), a John Cunningham virus (JCV) infection of the
brain [6]. PML is a demyelinating condition character-
ized by the degenerative loss of cerebral white matter
after infection by JCV, a normally latent polyomavirus
which becomes virulent in the presence of immunosup-
pression [7]. During therapy with NTZ, PML risk can
be stratified depending on three risk factors: anti-JCVicle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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than 2 years) and prior immunosuppressive therapy [8, 9].
It is important to identify other factors allowing better
identification of MS patients at high risk for PML. Schwab
and collaborators [10] investigated the expression of T
lymphocytes surface markers in NTZ-treated patients
before PML development. Their investigation suggested
L-selectin (CD62L) expressed on CD4+ T cells might
help identify MS patients at high risk for PML, since all
the eight patients who developed PML had a previous
blood sample showing a level of CD62L expression
below a hypothetical threshold [10].
The aim of this study was to investigate whether the
expression of CD62L is lower in NTZ-treated patients
than in patients treated with other drugs and to evaluate
levels of CD62L in a subset of NTZ-treated patients
throughout treatment.
Methods
Standard protocol approval, registration and patients
consent
We obtained peripheral blood samples from healthy in-
dividuals and from subjects with RRMS after they signed
a written informed consent approved by the Ethics
Committee of San Luigi Gonzaga University Hospital
(Ethic approval number 7777, March 25, 2013). The
blood samples were collected in 6 ml ethylenediamine-
tetraacetic acid (EDTA) Vacutainers (BD Biosciences,
Milan, Italy) and processed within the following 4 h.
This study was performed according to good clinical
practice and the Declaration of Helsinki.
Patients and healthy controls
We enrolled 225 patients with RRMS, aged 39 ± 10 years.





















16/10 (62 %) 44 ± 11
(22–60)
1.9 (0–8.5) 45 ± 38
IFNb
(n = 26)
15/11 (58 %) 36 ± 11
(24–65)
1.6 (0–5) 51 ± 48
NTZ
(n = 113)
76/37 (67 %) 37 ± 9
(19–60)
2.9 (0–8) 35 ± 24
RTX
(n = 18)
15/3 (83 %) 41 ± 10
(30–65)
4.4 (2–7) 1.25 (1–
FTY
(n = 23)
15/8 (65 %) 41 ± 9
(21–57)
3.1 (0–6.5) 15 ± 8 (
HD healthy donors, UT untreated multiple sclerosis patients, GA glatiramer acetate,
determined or not applicable, EDSS Expanded Disability Status Scale, nv naïve patiemetabolic disorders. Nineteen patients were untreated
(UT), 113 were treated with NTZ (300 mg iv every
28 days, duration 1–86 months), 26 were treated with
interferon-beta (IFNb), 26 were treated with glatira-
mer acetate (GA), 23 were treated with fingolimod
(FTY) and 18 were treated with rituximab (RTX).
At the time of enrolment, clinically definite MS was
diagnosed using the revised McDonald’s criteria [11].
Age- and sex-matched healthy donors (HD, n = 23)
with no previous history of any neurologic or
immune-mediated disease served as controls (Table 1).
We have also analysed samples from two PML/IRIS
(immune reconstitution inflammatory syndrome)
patients, who had discontinued NTZ treatment, and
we collected other four samples during 9 months
from a patient who developed clinical asymptomatic
PML while under NTZ. All patients underwent
periodic clinical and magnetic resonance imaging
(MRI) evaluations.
Blood samples and bio-banking
CRESM (Centro di Riferimento Regionale per la Sclerosi
Multipla) at University Hospital San Luigi, Orbassano,
Italy, houses a biological bank collecting samples from
HD and MS patients. The bio-bank stores biological
samples (cerebrospinal fluid (CSF), RNA, DNA, sera,
plasma and peripheral blood mononuclear cells (PBMC))
for research purposes. For this research, blood samples
were drawn just before NTZ-injection or during planned
routine visits in patients treated with other drugs.
PBMC were isolated from EDTA-treated blood by Lym-
phoprep density gradient centrifugation. Then, cells were
cryopreserved in liquid nitrogen using freezing medium:
60 % RPMI 1640 medium (Invitrogen Life Technologies,





(1–122) 13/26 IFNb; 9/26 nv; 4/26 IS
(3–147) 25/26 nv; 1/26 GA
(1–86) 52/113 IFNb; 23/113 GA; 13/113 IS; 12/113 nv; 6/
113 FTY; 7/113 other treatments
3) 1/18 IFNb; 1/18 GA; 5/18 FTY; 9/18 NTZ; 2/18 n.d.
1–29) 1/23 nv; 8/23 NTZ; 5/23 GA; 5/23 IFNb; 2/23 IS; 2/
23 other treatments
IFNb interferon-beta, NTZ natalizumab, RTX rituximab, FTY fingolimod, n.d. not
nt, IS immunosuppressive drug
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dimethyl sulfoxide (DMSO, Sigma-Aldrich, St Louis,
MO). All assays were performed on fresh frozen cells.
After gentle thawing at 37 °C, the cells were immediately
added to 5 mL RPMI 1640 supplemented with 10 % heat-
inactivated FBS and centrifuged to remove DMSO. The
samples were re-suspended in RPMI 1640 medium supple-
mented with 10 % heat-inactivated FBS and counted.
Flow cytometry
Non-specific sites of 2.5 × 105 cells were blocked with
rabbit immunoglobulins G (IgG, Sigma-Aldrich). Then,
the cells were incubated with fluorochrome-conjugated
monoclonal Ab (mAb) and isotype-matched negative
controls for 20 min at 4 °C. The following mAbs were
used: anti-human CD3 APC-Vio770 (Miltenyi Biotec,
Bergisch Gladbach, Germany), anti-human CD4 PE-Cy7
and anti-human CD62L FITC allophycocyanin (both
from BD Pharmingen, San Diego, CA) and isotype-
matched mAb (Miltenyi Biotec). After staining, the cells
were washed and re-suspended in PBS (Sigma-Aldrich)
supplemented with 0.2 % bovine serum albumin and
0.01 % sodium azide (both from Sigma-Aldrich). The
samples were collected and analysed using a CyAn ADP,
running Summit 4.3 analysis software (Beckman Coulter,
Brea, CA, USA). The living cells identified by propidium
iodide (Sigma-Aldrich) exclusion were gated according
to their light scatter properties to exclude cell debris.
Quality experiments have been performed (Additional
file 1: Figure S1) in order to evaluate whether the freeze-
thawing cycle could affect the quantification of CD62L
protein expression and to check the reproducibility of
the flow cytometric procedure and the stability of the
expression of CD62L on CD4+ T cells in frozen samples.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software, version 4; San Diego, CA,
USA). The differences between the two groups were
calculated with an unpaired, two-tailed, nonparametric
Mann-Whitney U test. The Student’s paired t test was
used to evaluate differences in the longitudinal studies.
Results
Expression of CD62L on CD4+ T cells in healthy donors
and in MS patients untreated or treated with IFNb, GA,
NTZ, FTY and RTX
To verify the impact of NTZ on the expression of CD62L
on the CD4+ T cell population, we tested our cohort at
least 15 days after freezing, as described by Schwab and
collaborators [10]. The strategy of CD62LCD4+ T cells
gating is described in Fig. 1. Compared to HD (46.75 % ±
9.8; mean ± SD) the expression of CD62L on CD4+ T cells
was significantly lower in patients treated with NTZ(33.68 % ± 12.7; p < 0.0001) (Fig. 2a). We have also ana-
lysed the expression of this molecule on CD4+ T cells
from UT naïve MS patients or from patients treated with
GA, IFNb, FTY and RTX. In patients treated with GA,
IFNb and UT, the expression of CD62L was higher than
in the NTZ-treated patients: 47.03 % ± 14.7 (p = 0.0001) in
the GA-treated patients, 42.95 % ± 18.9 (p = 0.0454) in the
IFNb-treated patients and 43.5 % ± 10.8 (p = 0.0028) in the
UT patients (Fig. 2a). The expression of CD62L was
extended to two second-line disease-modifying treatments
(DMTs), FTY and RTX, which had not been studied by
Schwab and collaborators. The expression of CD62L in
HD, UT, IFNb and GA was not significantly different from
the RTX group (41.11 % ± 14.63), whereas it was higher
than in the FTY group (28.76 % ± 11.42; HD: p < 0.0001,
UT: p = 0.0022, GA: p = 0.0002, respectively) (Fig. 2a). The
comparison of CD62L expression among second-line
treatment patients showed the percentage of CD62L was
higher in the RTX group than in the FTY (28.76 % ± 11.42;
p = 0.0121), but it was not statistically different from the
NTZ group (Fig. 2a).
Considering a low percentage of CD62LCD4+ might
represent a biomarker of the risk to develop PML, a
tentative threshold of risk was set up at 8.46 % repre-
senting the mean (34.08 %) of the long-term NTZ-
treated patients (>18 infusion) minus two times the SD
(12.81). Applying this threshold, 2 out of 80 long-term
treated patients (2.5 %) in the NTZ-treated group
showed an expression of CD62L below the threshold;
both patients had been treated with NTZ for more than
2 years (Fig. 2b). One patient treated with GA showed a
percentage of CD62L below the threshold.
To evaluate if the duration of NTZ treatment influ-
ences the level of CD62L, NTZ-treated patients were
stratified according to the number of infusions. NTZ
significantly reduced the expression of CD62L versus
the UT patients (p = 0.0200) and first-line therapies
(p = 0.0184) (Fig. 2b) already during the first year of
treatment; the reduction of the expression began dur-
ing the first semester of the treatment, and it reached
a statistically significant difference in the second se-
mester (UT p = 0.0226; first-line treatment p = 0.0220)
(Fig. 2c). The decreased CD62L expression persisted
in the following years with no statistically significant
fluctuations (Fig. 2b).
Longitudinal expression of CD62L during NTZ treatment
CD62L was measured in 35 patients during NTZ treatment
(7–82 infusions), three times at four monthly intervals to
evaluate the longitudinal fluctuations of L-selectin expres-
sion. The patients were selected in order to explore the full
range of CD62L expression, from low to high. In particular,
the first sample was categorized as low (L) if below the


























Fig. 1 Flow cytometry gating strategy. a A R1 gate was set on lymphocytes in the forward scatter (FS) versus side scatter (SS) dot plot.
Lymphocyte cells were then gated (R2) for the double positivity CD3+CD4+ markers, and finally, living cells were identified by propidium iodide
negativity (R3). A quadrant region for CD62LCD4+ T cells was then created using an isotype control. b Different dot plots from control subjects
or MS treated patients. A single subject for each treatment was shown
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>24 % and <43 %; 14 patients) and as high (H) if above the
75th percentile (CD62L >43 %, 11 patients) (Fig. 3a). The
categorization in the H, M and L groups was not
strictly dependent on the number of infusions as the
H group presented a number of infusions (median 62,
range 7–78) similar to the M group (median 44, range
7–82), although higher than the L group (median 33,
range 7–65, p = 0.0302) (Fig. 3b). When we considered
the second and third draw, the percentage of CD62L
was significantly lower than in the first one (p =
0.0087, p = 0.0094, respectively) with no differences
between the second and the third tap (Fig. 3a). The
longitudinal study showed that 1 out of 35 patients
(3 %) presented one of the three samples below the
tentative threshold.Expression of CD4CD62L+ after NTZ discontinuation
Six patients discontinued NTZ treatment because they
considered the risk of PML too high (Table 2). CD62L
was studied during NTZ treatment, from 16 to 71 infu-
sions, and 3 to 5 months after withdrawal (Table 2).
Three out of six patients showed a low level of CD62L+
during treatment, which reverted to UT values after
discontinuation as shown in Table 2. The expression of
CD62L remained almost unchanged in two patients
who had values similar to the mean of the NTZ group,
while in patient #6, CD62L expression decreased in
32 % 3 months after discontinuation, although it was
not below the tentative threshold and remained in the
medium group between 25th and 75th percentile. The
patients were monitored by MRI to evaluate the status
disease after NTZ discontinuation. Only one patient
Spadaro et al. Journal of Neuroinflammation  (2015) 12:146 Page 5 of 9(pt #3) with the unvaried CD62L expression had a
relapse (Table 2).
Expression of CD62L in a single patient during the
development of asymptomatic PML
We had the opportunity to examine one NTZ-treated
female patient four times in December 2013, March, July
and August 2014 in the meanwhile she was developing
an asymptomatic PML. At the same time as CD62L
expression analysis, the patient underwent neurological
examination and MRI scans, which were reported as
negative for PML in December and March and stronglyFig. 2 CD62L evaluation in HD and MS patients. a Comparison of different tre
IFNβ (26, solid triangle), GA (26, solid diamond), NTZ (113, solid circle), FTY (23, o
tentative threshold (8.46 %), the solid line indicates the mean. b Stratification o
the first year of treatment. CD62L in the first semester, 1–6 months (15 patien
square), and in first-line drug-treated patients (52 patients, open diamond). Thesuggestive for PML in July. In August, the patient was
admitted to the hospital: the neurological examination was
negative, a new MRI showed an enlargement of the PML-
suspected lesion and 80 JCV DNA copies per ml were
detected in the cerebrospinal fluid (Fig. 4). A diagnosis of
asymptomatic PML was made, and NTZ was discontinued.
A re-evaluation of the MRI scan performed in March
revealed a small T2 lesion in the occipital right lobe, where
the larger lesion was subsequently detected in July (Fig. 4).
CD62L showed a value of 23.21 % in December and of
26.14 % in March; the blood tap in July showed a value of
10.65 % which is nearby the tentative threshold of 8.46 %atments. CD62L evaluation in HD (23, solid square), UT (19, open square),
pen triangle) and RTX (18, asterisk) groups. The dotted line displays the
f NTZ analysis by year of treatment. c The first and second semesters of
ts; black square), the second semester, 7–12 months (11 patients; grey
statistical differences were calculated with the Mann-Whitney U test
Fig. 3 Longitudinal study of the NTZ-treated patients. a Thirty-five
NTZ patients were analysed three times during treatment: first,
second and third sampling. The overall results of the first sample
were divided into three regions. High, low and medium indicate
respectively the region above the 75th percentile (H; black square),
that below the 25th percentile (L; solid circle) and the region
between H and L (M; open diamond). The statistical differences were
calculated with Student’s paired t test. b Number of infusions in the
three different groups. The statistical differences were calculated
using Mann-Whitney U test
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tomatic PML was made in August, the value of CD62L was
46.52 % (Fig. 4).
Expression of CD62L in PML/IRIS cases
We also had the possibility to evaluate the percentage of
CD62L in two cases of PML, during the IRIS phase,
4 months after NTZ treatment had been discontinued:
CD62L values were similar to the mean value of the
NTZ-treated group (Fig. 4).
Discussion
The main goal of this research was to test whether NTZ
treatment has a specific impact on CD62L expression inCD4+ T cells as suggested by Schwab and collaborators
[10]. This issue is relevant as low levels of CD62L were
suggested as a potential marker for PML risk stratifica-
tion in NTZ-treated patients [10].
The CD62L is a key adhesion molecule which regulates
both the migration of leukocytes at sites of inflammation
and the recirculation of lymphocytes between blood and
lymphoid tissues. In our work, we analysed separately the
first-line drugs (IFNb and GA). The data are consistent
with those already reported since the patients treated with
NTZ showed a lower percentage of CD62LCD4+ T cells
than the patients treated with IFNb (p = 0.0454) and GA
(p = 0.0001). Although data in literature show that the GA
had no impact on the expression of the T cell surface acti-
vation markers such as CD62L in animal model [12], in
our study, a GA-treated patient showed a low percentage
of CD62LCD4+ T cells for no apparent reason. Monitoring
the medical record, 4 months later CD62L analysis, the
patient had a serious infection resulting in prolonged
hospitalization. This data shows how this might be a cor-
relation between the low percentage of CD62L and the
subsequent development of infections even though this is
not closely related to MS. We have also studied in our
research the impact of two second-line DMTs on CD62L.
RTX does not influence CD62L expression on CD4+ T
cells, since we have not detected any differences with HD
controls, UT, GA- and IFNb-treated patients (Fig. 2). FTY
induced a decreased CD62L expression, similarly to NTZ
(Fig. 2). The peculiarity of CD62L is that it acts as a
“homing receptor” for leukocytes to enter secondary
lymphoid tissues via high endothelial venules. The func-
tion of FTY is the segregation of lymphocytes in the
lymph nodes. Previous reports showed FTY mainly influ-
ences naïve and central memory cells [13], and probably
for these reasons, a high percentage of CD62LCD4+ T
cells are absent in the blood of our patients. Furthermore,
different patients were previously treated with NTZ and
this could influence the expression of CD62L on CD4+ T
cells. The phenomenon we observed is very interesting
and deserves a dedicated study to evaluate the expression
of CD4CD62L+ T cells on a broader population of FTY-
treated patients and its stability during time.
In Fig. 2, we took a picture of the first sampling by
evaluating all the available patients we had at that time.
Then, we stratified the patients according to the number
of given infusions, and we noticed only the first year was
statistically different, while the next was no longer (Fig. 2b).
These data suggest an implication of NTZ in the variation
of CD62L expression on CD4+ T cells. To evaluate the
effect of NTZ on the expression of CD62L in the first year,
we have separated the first 6 months of treatment and the
second ones. Our results show a persistent CD62L low
expression if you continue the treatment, and it disappears
after treatment discontinuation. In the group of patients
Table 2 Clinical features and percentage of CD62L positive CD62LCD4+ T cells in 6 patients who discontinued the NTZ treatment
During NTZ infusion After NTZ withdrawal
JCV index Number of infusion CD62LCD4 (%) Number of months CD62LCD4 (%) MRI Relapse
Pt #1 3.498 40 5.65 5 49.07 Neg None
Pt #2 2.488 16 16.34 3 56.48 Neg None
Pt #3 2.696 20 35.44 4 32.21 Pos 1
Pt #4 2.034 71 44.50 3 42.32 Neg None
Pt #5 1.366 66 15.83 4 56.59 Neg None
Pt #6 2.304 32 41.18 3 27.78 Neg None
Neg unvaried number of lesions compared to previous MRI
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significant increase of CD62L percentage belonged to the
25th percentile group (pt #1, pt #2, pt #5). Moreover, the
patient (pt #6) who had a decrease of CD62L expression
remained in the medium group. Only one patient (pt #3),
who had an unchanged value of CD62L, had a relapse
4 months after NTZ suspension (MRI pos, see Table 2): this
is an indication that CD62L is a marker of infections and
not of the MS relapse activity. However, all patients were
monitored by MRI 2–3 months after discontinuation, andFig. 4 Longitudinal analysis of CD62L expression in one patient who devel
reactivation/IRIS phase of PML. The PML patient was analysed by MRI and b
diamond) nearby the threshold (dotted line) was found in July, when MRI w
80 copies of JCV in the cerebrospinal fluid, in the absence of clinical manif
phase, 4 months after PML diagnosis and NTZ withdrawalthis exam was unchanged compared to the previous result
in five patients out of six.
In the whole subsets of patients, freeze-thawed cells
showed a lower percentage of CD62L expression than
fresh cells, but the decrease was more relevant in NTZ-
treated patients (Additional file 1: Figure S1). Our data
confirmed prolonged interaction between NTZ and
PBMC expressing α4 integrins induces increased cell
activation causing easier shedding of CD62L [14, 15] or
reduced cell viability.oped PML and CD62L expression in two other patients during the MS
y flow cytometry four times during treatment. The value (solid
as suggestive of PML. In August, PML was diagnosed by detection of
estation. The black circles identify two patients in the reactivation/IRIS
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age of PBMC CD62L+ cells, a phenomenon already
observed on polymorphonuclear leukocytes [16], the
procedures of PBMC collection, banking and freeze-
thawing are crucial and small variations could explain
the lower percentage of CD62LCD4+ T cells we found
in comparison with the Schwab study [10]. Staining and
gating of positive cells do not seem to influence the
results as the reproducibility of flow cytometry quantifi-
cation of CD62L-positive cells was very good in the
same frozen sample (Additional file 1: Figure S1).
The seminal work on the role of CD62L as a bio-
marker for PML risk stratification showed all the eight
patients, who later developed PML, had a value of
CD62L below a tentative threshold [10]. In this work,
the longitudinal data of a patient who later developed
PML support the role of CD62L as a risk biological
marker. In order to get a precise comparison with the
work of Schwab and colleagues [10], we should calcu-
late the threshold value as the mean minus twice the
standard deviation of the percentage of CD62L in long-
term NTZ-treated patients. A value of CD62L nearby
to the tentative threshold was detected in the clinically
asymptomatic phase of the disease, and a value in the
lower 25th percentile was detected when MRI was
judged negative for PML (Fig. 4). This observation
opens a question about the establishment of threshold
risk. In this research, we found a correlation between
the low percentage of CD62L and the development of a
severe infection. A greater number of observations are
required to establish a threshold, and it is also neces-
sary to evaluate critically whether the values obtained
could be arranged in the 25th percentile or below the
long-term NTZ-treated patients threshold or if it is
better to calculate the threshold based on the first-line
drug group since the majority of NTZ patients (75
patients out of 113, Table 1) starts NTZ after the first-
line drug treatment.
Previous studies have shown that NTZ-treated MS
patients have an increased pool of T cells and other
lymphocytes in the blood compartment [17, 18] which
may be enriched in T cells with an increased activation
state. The percentage of CD62L in each patient fluctu-
ates in time; in fact, the longitudinal measurements in
the same patients showed 3 % of the patients tested
three times 4 months apart had one single value below
the empirically established threshold (Fig. 3), and the
value of CD62L decreased during time. Considering
PML risk increases with time on treatment [19], in our
analysis, we found patients with a percentage of CD62L
below threshold in the fourth and seventh year (Fig. 2b).
The patients with CD62L low expression will be closely
monitored by MRI and CD62L analysis. In addition to
the existing parameters, the analysis of CD62L could beanother parameter to evaluate patients’ health and their
risk to develop PML.
Conclusions
Our investigation confirms that a low percentage of
CD62LCD4+ T cells could represent a potential bio-
marker for PML risk stratification. A multicentre study
enrolling a larger number of patients using homoge-
neous flow cytometry protocol is mandatory to establish
a PML risk threshold and to define the timing of
CD62LCD4+ quantification.
Additional file
Additional file 1: Figure S1 Set up procedure. A Expression of CD4+ T
cells. PBMCs were analysed before (solid symbol) and after (open symbol)
freezing in group A (six patients, four HD and two first-line treated MS;
squares) and NTZ (five patients; diamonds). B Expression of CD62L on
CD4+ T cells. PBMCs were analysed before (solid symbol) and after (open
symbol) freezing in group A (six patients, four HD and two first-line
treated MS; squares) and NTZ (five patients, diamonds). After freezing
CD62L expression decreased by 31 % in the CTRL group and by 33 % in
the NTZ group. C Analysis of stability and reproducibility. The frozen
samples from the same patient were evaluated for CD62L expression in
two different work sessions 3 months apart. The statistical differences
were calculated with Student's paired t test.
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